Our partner was a clinical-stage biopharmaceutical company pioneering advancements in targeted protein degradation therapeutics. As the first to focus exclusively on protein degradation, they developed a platform technology recognized as the most advanced in the field.

This critical hire served as a vital link to investigators and key opinion leaders within the oncology community. They collaborated with these experts to shape clinical trial strategies and identify suitable investigators for studies. Acting as a strategic and medical leader during trial execution, they monitored safety, analyzed data, and guided its presentation. Additionally, they responded to inquiries from practitioners, investigators, IRBs, regulatory bodies, and vendors while fostering relationships with KOLs, external advisors, and collaborators to advance the organization’s oncology initiatives.